GSK plc has announced FDA approval of Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone (BVd) for adults with relapsed or refractory multiple myeloma who have received at least two prior therapies, including a proteasome inhibitor and an immunomodulatory agent. The approval is based on data from the phase III DREAMM-7 trial, which showed Blenrep BVd reduced the risk of death by 51% (HR 0.49; 95% CI: 0.32–0.76) and tripled median progression-free survival to ...